GZ17-6.02 Effective in Killing Multiple Myeloma Cells, Other Benefits When Combined With Bortezomib

by | Mar 13, 2024 | Myeloma News | 0 comments

Source: Pharmacy Times articles

The combination of GZ17-6.02 and bortezomib reduced of HDAC, and as a result ATG13 phosphorylation was enhanced, BAK levels increased, and BCL-XL levels were reduced.
Read More

Submit a Comment